R188e-SSSLipiodol : Development of a Potential Treatment for HCC from Bench to Bedside
Joint Authors
Garin, Etienne
Lepareur, Nicolas
Ardisson, Valérie
Noiret, Nicolas
Source
International Journal of Molecular Imaging
Issue
Vol. 2012, Issue 2012 (31 Dec. 2012), pp.1-9, 9 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2012-02-22
Country of Publication
Egypt
No. of Pages
9
Main Subjects
Abstract EN
Hepatocellular carcinoma (HCC) is the 5th most common tumour worldwide and has a dark prognosis.
For nonoperable cases, metabolic radiotherapy with Lipiodol labelled with β-emitters is a promising therapeutic option.
The Comprehensive Cancer Centre Eugène Marquis and the National Graduate School of Chemistry of Rennes (ENSCR) have jointly developed a stable and efficient labelling of Lipiodol with rhenium-188 (Eβmax=2.1 MeV) for the treatment of HCC.
The major “milestones” of this development, from the first syntheses to the recent first injection in man, are described.
American Psychological Association (APA)
Lepareur, Nicolas& Ardisson, Valérie& Noiret, Nicolas& Garin, Etienne. 2012. R188e-SSSLipiodol : Development of a Potential Treatment for HCC from Bench to Bedside. International Journal of Molecular Imaging،Vol. 2012, no. 2012, pp.1-9.
https://search.emarefa.net/detail/BIM-459724
Modern Language Association (MLA)
Lepareur, Nicolas…[et al.]. R188e-SSSLipiodol : Development of a Potential Treatment for HCC from Bench to Bedside. International Journal of Molecular Imaging No. 2012 (2012), pp.1-9.
https://search.emarefa.net/detail/BIM-459724
American Medical Association (AMA)
Lepareur, Nicolas& Ardisson, Valérie& Noiret, Nicolas& Garin, Etienne. R188e-SSSLipiodol : Development of a Potential Treatment for HCC from Bench to Bedside. International Journal of Molecular Imaging. 2012. Vol. 2012, no. 2012, pp.1-9.
https://search.emarefa.net/detail/BIM-459724
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-459724
